### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3

#### HALOZYME THERAPEUTICS INC

Form 3

November 13, 2006

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

(Print or Type Responses)

1. Title of Security

(Instr. 4)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement HALOZYME THERAPEUTICS INC [HTI] A Fallon William J (Month/Day/Year) 11/06/2006 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 11588 SORRENTO VALLEY (Check all applicable) ROAD, Â SUITE 17 (Street) 6. Individual or Joint/Group 10% Owner Director \_X\_\_ Officer Other Filing(Check Applicable Line) (give title below) (specify below) \_X\_ Form filed by One Reporting Vice President, Mfg. and Ops Person SAN DIEGO, CAÂ 92121 Form filed by More than One Reporting Person (City) (State) (Zip)

### Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned (Instr. 4)

4. Nature of Indirect Beneficial Ownership Ownership Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Derivative Security: Security Direct (D) or Indirect (I)	(Instr. 5)	

## Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3

(Instr. 5)

Option to purchase Common Stock

11/09/2007 11/09/2016

Common Stock

160,000 \$ 2.67

Â D

Other

# **Reporting Owners**

Relationships Reporting Owner Name / Address Director 10% Owner Officer Fallon William J 11588 SORRENTO VALLEY ROAD Â

SUITE 17 SAN DIEGO, CAÂ 92121 Â Vice President, Mfg. and Ops

# **Signatures**

William J Fallon 11/10/2006 \*\*Signature of Date Reporting Person

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).